Evidence Hub

Evaluation of PDA‑PLL Nanoparticles for siRNA Delivery and ROS Scavenging in Rat Osteoarthritis

Hao Hu, Gui-Ju Chen, Yang Hu, Nan-Nan Ding, Guo-Rui Jin, Hui Xing, Wen-Ming Tao

International Journal of Nanomedicine, 2026

Abstract

Introduction Osteoarthritis (OA) is a prevalent chronic inflammatory disease in which elevated TNF-α and excessive reactive oxygen species (ROS) play central roles. These two pathological factors mutually reinforce each other—TNF-α induces ROS production while ROS upregulates TNF-α expression—forming a vicious cycle that propels disease progression. However, current therapies offer only symptomatic relief without halting this process. To address this, we developed polydopamine-poly(L-lysine) (PDA-PLL) nanoparticles as a dual-functional platform that combines PDA-mediated ROS scavenging with PLL-facilitated TNF-α siRNA delivery. Methods PDA-PLL nanoparticles were synthesized and systematically characterized, and then their gene transfection efficiency and ROS scavenging capacity were evaluated. Finally, their therapeutic efficacy against OA was assessed in chondrocytes and in animal models. Results Biocompatibility was evidenced by low in-vitro cytotoxicity and the absence of systemic toxicity in rats by hematology, biochemistry, and histopathology. Agarose gel electrophoresis demonstrated their strong nucleic acid loading capability, and fluorescence imaging further revealed that PDA-PLL nanoparticles enabled highly efficient gene transfection in OA chondrocytes. PDA-PLL nanoparticles exhibited dose-dependent scavenging of O2•−, •OH, and H2O2 in cell-free assays and lowered intracellular ROS in OA chondrocytes; critically, co-delivery of TNF-α siRNA further reduced ROS…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free